DexCom (NasdaqGS:DXCM) experienced an 12% decline over the past week, during which the company transitioned its audit from Ernst & Young to Deloitte & Touche, and appointed Jon Coleman as Chief ...

At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system, 1 showing an overall mean absolute relative difference (MARD) of 8.0% ...

A survey conducted by the continuous glucose monitor maker Dexcom found that just over half of healthcare providers ranked technology and education as having larger impacts when it comes to ...

In its fourth quarter 2024 investor letter, Sands Capital Select Growth Fund emphasized stocks such as DexCom, Inc. (NASDAQ:DXCM). DexCom, Inc. (NASDAQ:DXCM) is a medical device company that ...

DexCom, Inc. (NASDAQ: DXCM), a global leader in glucose biosensing, today announced the launch of its first multi-region report, the "Dexcom State of Type 2 Report: Access and Attitudes Across ...

Dexcom is preparing to launch a 15-day version of its G7 continuous glucose monitor, based on data presented Thursday at the Advanced Technologies & Treatments for Diabetes conference. Dexcom pointed ...

Medtech manufacturers gathered in Amsterdam to discuss the latest innovations for managing diabetes. Here are three highlights from the first day of the conference: 1. Dexcom previews new data for ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

his critics. many are falling in line. stay with us. >> maybe if he hadn't been such with it. i'm still not sure that you're repentant. >> united states of scandal with jake tapper tonight at nine on ...